Alternative Pain Medications to NSAIDs

First-Line Non-NSAID Options

The American Geriatrics Society recommends using acetaminophen 650-1000 mg every 4-6 hours (maximum 4000 mg/day) as the preferred first-line pharmacologic treatment for mild to moderate pain 1, 2, 3
Acetaminophen provides pain relief comparable to NSAIDs without gastrointestinal, cardiovascular, or renal toxicity risks 1
For localized pain, the American Geriatrics Society suggests using topical NSAIDs (such as diclofenac gel) or capsaicin cream as effective alternatives 1, 4

The Annals of Oncology recommend considering tramadol or combination products containing acetaminophen plus codeine (up to 4000 mg acetaminophen and 240 mg codeine daily) for moderate pain not controlled by acetaminophen 2, 5
Other weak opioids include codeine, dihydrocodeine, or low doses of strong opioids like morphine or oxycodone 2, 5

The Annals of Oncology suggest using morphine (oral route preferred), hydromorphone, or oxycodone in both immediate-release and modified-release formulations for severe pain 2, 5, 3
Opioids should be used judiciously with careful assessment of benefits versus risks, particularly for aberrant drug-related behaviors with long-term use 3

For neuropathic pain (diabetic neuropathy, postherpetic neuralgia), the MMWR Recommendations and Reports recommend using duloxetine (SNRI antidepressant) or anticonvulsants pregabalin, gabapentin, or oxcarbazepine 4
For fibromyalgia, the MMWR Recommendations and Reports suggest using duloxetine, milnacipran (SNRI antidepressants), or pregabalin/gabapentin (anticonvulsants) 4
For osteoarthritis, duloxetine has small to moderate benefits and is more effective in older patients (>65 years) and those with knee osteoarthritis 4
For chronic low back pain with insufficient response to nonpharmacologic approaches, consider duloxetine or skeletal muscle relaxants 4, 3

Schedule analgesics around-the-clock rather than as-needed for consistent pain control 2, 5
Provide breakthrough doses (usually 10% of total daily dose) for transient pain exacerbations, and increase the baseline analgesic regimen if more than 4 breakthrough doses are needed daily 2, 5
Monitor for and manage opioid side effects including constipation, nausea, and drowsiness, and ensure optimal dosing of each component when using multimodal analgesia 3, 6

Initiate oral oxycodone 5–10 mg every 4–6 hours as needed, combined with scheduled acetaminophen 1000 mg every 6 hours (maximum 4000 mg/day), and add topical diclofenac gel applied 3–4 times daily for localized relief. 7

High‑certainty evidence shows that adding acetaminophen to an opioid reduces pain by 1.71 cm on a 10‑cm visual analog scale within 1–7 days compared with placebo, confirming superior analgesia for severe musculoskeletal pain. 7
Continuing scheduled acetaminophen 1000 mg q6 h alongside opioids lowers total opioid consumption by 20–30 % while preserving equal or better pain control. 7

The World Health Organization (WHO) analgesic ladder recommends escalation to Level III (strong opioid) when NSAIDs fail to control severe structural shoulder injury pain. 8
WHO and oncology guidelines list morphine, oxycodone, and hydromorphone as the preferred strong opioids for severe pain, with oral administration as the preferred route. [8][9]

Topical diclofenac gel applied 3–4 times daily provides localized analgesia with minimal systemic absorption and is especially valuable when oral NSAIDs are ineffective or contraindicated. 7

Prescribe a prophylactic bowel regimen (stimulant laxative + stool softener) at opioid initiation to prevent predictable constipation. 9
Offer anti‑emetic therapy (prochlorperazine 5–10 mg q6–8 h or metoclopramide 10 mg q6–8 h) to manage transient opioid‑induced nausea. 9
Reassess pain daily using a 0–10 functional pain scale; adjust dosing to achieve symptom relief without excessive sedation. This monitoring approach is endorsed by respiratory and otolaryngology societies. [9][10]

Never prescribe opioids without scheduled acetaminophen; the combination reduces opioid requirements by 20–30 % while maintaining analgesic efficacy. 7
Incorporate topical NSAIDs when oral NSAIDs have failed, as they achieve high local tissue concentrations with negligible systemic exposure and can add to overall analgesia. 7
Discontinue ineffective oral NSAIDs once opioid therapy is initiated, or replace them with topical formulations to avoid unnecessary systemic NSAID exposure. 7